The use of bezafibrate and medroxyprogesterone acetate to potentiate the therapeutic effects of retinoids in myelodysplasia and acute myeloid leukaemia

Trial Profile

The use of bezafibrate and medroxyprogesterone acetate to potentiate the therapeutic effects of retinoids in myelodysplasia and acute myeloid leukaemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2005

At a glance

  • Drugs Bezafibrate (Primary) ; Medroxyprogesterone (Primary) ; Retinoids
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms PORIDIM
  • Most Recent Events

    • 04 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top